| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| W M Drake, S J Howell, J P Monson, S M Shale. Optimizing gh therapy in adults and children. Endocrine reviews. vol 22. issue 4. 2001-10-18. PMID:11493578. |
assessment of optimal gh replacement is made difficult by the apparent diverse actions of gh in health, concern about the avoidance of iatrogenic acromegaly, and the growing realization that an individual's risk of developing certain cancers may, at least in part, be influenced by cumulative exposure to the chief mediator of gh action, igf-i. |
2001-10-18 |
2023-08-12 |
human |
| Y Lorcy, S Dejager, P Chanso. Time course of GH and IGF-1 levels following withdrawal of long-acting octreotide in acromegaly. Pituitary. vol 3. issue 3. 2001-10-11. PMID:11383486. |
time course of gh and igf-1 levels following withdrawal of long-acting octreotide in acromegaly. |
2001-10-11 |
2023-08-12 |
Not clear |
| I Shimon, Z R Cohen, Z Ram, M Hadan. Transsphenoidal surgery for acromegaly: endocrinological follow-up of 98 patients. Neurosurgery. vol 48. issue 6. 2001-10-11. PMID:11383725. |
strict criteria for insulin-like growth factor i normalization and even lower gh levels (<1 ng/ml) are now suggested to define cure of acromegaly, but the evidence does not yet support such low gh levels in epidemiological follow-up. |
2001-10-11 |
2023-08-12 |
Not clear |
| J J Díez, P Iglesias, A Gómez-Pa. Growth hormone responses to oral glucose and intravenous thyrotropin-releasing hormone in acromegalic patients treated by slow-release lanreotide. Journal of endocrinological investigation. vol 24. issue 5. 2001-10-11. PMID:11407648. |
the aim of this study was to assess gh response to oral glucose tolerance test (ogtt) and trh stimulation test in a group of 10 patients with active post-operative acromegaly before and after long-term slow-release (sr) lanreotide therapy (30 mg im every 10-14 days). |
2001-10-11 |
2023-08-12 |
Not clear |
| C A Jaffe, W Pan, M B Brown, R DeMott-Friberg, A L Barka. Regulation of GH secretion in acromegaly: reproducibility of daily GH profiles and attenuated negative feedback by IGF-I. The Journal of clinical endocrinology and metabolism. vol 86. issue 9. 2001-10-11. PMID:11549676. |
regulation of gh secretion in acromegaly: reproducibility of daily gh profiles and attenuated negative feedback by igf-i. |
2001-10-11 |
2023-08-12 |
human |
| C A Jaffe, W Pan, M B Brown, R DeMott-Friberg, A L Barka. Regulation of GH secretion in acromegaly: reproducibility of daily GH profiles and attenuated negative feedback by IGF-I. The Journal of clinical endocrinology and metabolism. vol 86. issue 9. 2001-10-11. PMID:11549676. |
gh hypersecretion is a hallmark of acromegaly. |
2001-10-11 |
2023-08-12 |
human |
| C A Jaffe, W Pan, M B Brown, R DeMott-Friberg, A L Barka. Regulation of GH secretion in acromegaly: reproducibility of daily GH profiles and attenuated negative feedback by IGF-I. The Journal of clinical endocrinology and metabolism. vol 86. issue 9. 2001-10-11. PMID:11549676. |
in this study we investigated whether gh secretion in acromegaly 1) has a reproducible circadian pattern and 2) is inhibited by exogenous igf-i. |
2001-10-11 |
2023-08-12 |
human |
| C A Jaffe, W Pan, M B Brown, R DeMott-Friberg, A L Barka. Regulation of GH secretion in acromegaly: reproducibility of daily GH profiles and attenuated negative feedback by IGF-I. The Journal of clinical endocrinology and metabolism. vol 86. issue 9. 2001-10-11. PMID:11549676. |
by harmonic analysis, nocturnal augmentation of gh was maintained, and maximum daily gh occurred at approximately 2300 h. these data demonstrate that the pattern of gh secretion in acromegaly is not random, but is highly preserved with 24-h periodicity. |
2001-10-11 |
2023-08-12 |
human |
| T C Voss, L R Goldman, S L Seek, T L Miller, K E Mayo, A Somogyvari-Vigh, A Arimura, D L Hurle. GH mRNA levels are elevated by forskolin but not GH releasing hormone in GHRH receptor-expressing MtT/S somatotroph cell line. Molecular and cellular endocrinology. vol 172. issue 1-2. 2001-09-20. PMID:11165046. |
taken together, these data indicate that although mtt/s cells express the ghrh-r, ghrh cannot stimulate adenylate cyclase to increase gh transcription due to constitutive elevation of camp levels, by a means that may be similar to that in cases of acromegaly not caused by oncogenic gsp mutations. |
2001-09-20 |
2023-08-12 |
Not clear |
| H Hasegawa, M Onda, N Matsukura, Z Naito, H Maruyama, A Tokunag. Hemorrhagic gastric carcinoma in an acromegalic patient. Journal of Nippon Medical School = Nippon Ika Daigaku zasshi. vol 68. issue 3. 2001-08-30. PMID:11404775. |
this patient showed typical clinical features of acromegaly, with increased serum growth hormone (gh) and insulin-like growth factor i (igf-i) level. |
2001-08-30 |
2023-08-12 |
Not clear |
| N H Othman, S Ezzat, K Kovacs, E Horvath, E Poulin, H S Smyth, S L As. Growth hormone-releasing hormone (GHRH) and GHRH receptor (GHRH-R) isoform expression in ectopic acromegaly. Clinical endocrinology. vol 55. issue 1. 2001-08-30. PMID:11453963. |
bronchial endocrine neoplasms causing acromegaly due to ectopic production of growth hormone (gh)-releasing hormone (ghrh) have been reported. |
2001-08-30 |
2023-08-12 |
human |
| P J Trainer, W M Drake, L A Perry, N F Taylor, G M Besser, J P Monso. Modulation of cortisol metabolism by the growth hormone receptor antagonist pegvisomant in patients with acromegaly. The Journal of clinical endocrinology and metabolism. vol 86. issue 7. 2001-08-02. PMID:11443156. |
pegvisomant is a gh receptor antagonist and highly efficacious new treatment for acromegaly. |
2001-08-02 |
2023-08-12 |
Not clear |
| P J Trainer, W M Drake, L A Perry, N F Taylor, G M Besser, J P Monso. Modulation of cortisol metabolism by the growth hormone receptor antagonist pegvisomant in patients with acromegaly. The Journal of clinical endocrinology and metabolism. vol 86. issue 7. 2001-08-02. PMID:11443156. |
these data 1) indicate that blockade of gh action with pegvisomant in patients with acromegaly is associated with reversal of the inhibition of 11beta-hydroxysteroid dehydrogenase and correction of cortisol metabolism, and 2) suggest that in active acromegaly, cortisol clearance is accelerated and that this is reversed by successful treatment. |
2001-08-02 |
2023-08-12 |
Not clear |
| P Marzullo, C Di Somma, K L Pratt, J Khosravi, A Diamandis, G Lombardi, A Colao, R G Rosenfel. Usefulness of different biochemical markers of the insulin-like growth factor (IGF) family in diagnosing growth hormone excess and deficiency in adults. The Journal of clinical endocrinology and metabolism. vol 86. issue 7. 2001-08-02. PMID:11443159. |
the diagnostic approach to acromegaly and gh deficiency frequently includes measurement of several components of the insulin-like growth factor (igf) system. |
2001-08-02 |
2023-08-12 |
human |
| K Obuobie, V Mullik, C Jones, R John, A E Rees, J S Davies, M F Scanlon, J H Lazaru. McCune-Albright syndrome: growth hormone dynamics in pregnancy. The Journal of clinical endocrinology and metabolism. vol 86. issue 6. 2001-07-05. PMID:11397839. |
these data support a picture of gh suppression during pregnancy in acromegaly associated with mccune-albright syndrome, shown best with assay b, which discriminates between gh and hpl. |
2001-07-05 |
2023-08-12 |
human |
| K Obuobie, V Mullik, C Jones, R John, A E Rees, J S Davies, M F Scanlon, J H Lazaru. McCune-Albright syndrome: growth hormone dynamics in pregnancy. The Journal of clinical endocrinology and metabolism. vol 86. issue 6. 2001-07-05. PMID:11397839. |
these data suggest that gh secretion in a pregnant acromegalic with the mccune-albright syndrome may not be entirely autonomous, as seen in classic acromegaly, but may be associated with a degree of negative feedback control that could be exerted by a circulating factor of placental origin, probably hpl or placental gh. |
2001-07-05 |
2023-08-12 |
human |
| A Colao, D Ferone, P Marzullo, P Cappabianca, S Cirillo, V Boerlin, I Lancranjan, G Lombard. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. The Journal of clinical endocrinology and metabolism. vol 86. issue 6. 2001-07-05. PMID:11397887. |
the effects of a 12- to 24-month treatment with depot long-acting octreotide (oct-lar) on hormone profile, tumor mass, and clinical symptoms were reported in 36 patients with active acromegaly [gh, 34.2 +/- 5.6 microg/l; insulin-like growth factor i (igf-i), 784.5 +/- 40.4 microg/l]. |
2001-07-05 |
2023-08-12 |
Not clear |
| A Colao, D Ferone, P Marzullo, P Cappabianca, S Cirillo, V Boerlin, I Lancranjan, G Lombard. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. The Journal of clinical endocrinology and metabolism. vol 86. issue 6. 2001-07-05. PMID:11397887. |
in conclusion, long-term treatment with oct-lar was effective in controlling gh and igf-i hypersecretion in most patients with acromegaly, when applied either as primary therapy or as adjunctive therapy after surgery. |
2001-07-05 |
2023-08-12 |
Not clear |
| M Volterrani, A Giustina, F Manelli, M A Cicoira, R Lorusso, A Giordan. Role of growth hormone in chronic heart failure: therapeutic implications. Italian heart journal : official journal of the Italian Federation of Cardiology. vol 1. issue 11. 2001-05-31. PMID:11110515. |
patients with acromegaly have an increased propensity to develop ventricular hypertrophy and cardiovascular diseases; impaired cardiac efficiency can also be observed in patients with gh deficiency. |
2001-05-31 |
2023-08-12 |
Not clear |
| S Okada, J J Kopchic. Biological effects of growth hormone and its antagonist. Trends in molecular medicine. vol 7. issue 3. 2001-05-21. PMID:11286784. |
high levels of gh can lead to gigantism or a clinical syndrome termed acromegaly and has been implicated in diabetic eye and kidney damage. |
2001-05-21 |
2023-08-12 |
Not clear |